In early 2026, Zomato founder and CEO Deepinder Goyal sparked widespread online discussion after appearing on a podcast wearing a small metallic device near his temple. The gadget, quickly dubbed Temple, triggered curiosity, memes, and even unsolicited advice – much of it warning people not to buy it.
However, the most important fact remains: Temple is not a consumer product. It is not available for purchase, preorder, or sale in any form.
According to verified reports and Goyal’s own explanations, Temple is an experimental research prototype developed as part of his personal work around the Gravity Ageing Hypothesis. The device is designed to explore real-time brain blood flow monitoring, and the work is still firmly in the research phase. No official claims, benchmarks, or commercial timelines have been announced.
Goyal has clarified that scientific work is ongoing, and that the team is months away from introducing preview devices to the public – if at all. Importantly, no data has been released for public evaluation, and no marketing or commercial communication has been made.
Despite this, several doctors and influencers have publicly cautioned people against buying or trusting the device. While medical skepticism is valid and necessary, experts have also noted that there is currently nothing to validate or invalidate, since the device is not being sold or promoted as a health product yet. Neurologists and health professionals have pointed out that technologies claiming to measure cerebral blood flow require rigorous clinical trials and peer-reviewed validation – processes that happen before commercial launch, not before research exploration.
Advising people not to buy an “unvalidated” product that doesn’t exist in the market may be premature. Until Temple reaches a stage where data, science, and availability are shared publicly, curiosity, informed discussion, and constructive scrutiny are more relevant than early judgement.
If and when Temple becomes a consumer-facing product, that will be the right moment for evaluation, advice, and critique. Until then, allowing Indian startups and founders the space to experiment responsibly may be just as important as healthy skepticism.
